Suraksha Diagnostic Limited announced the outcome of its Board of Directors meeting held on Thursday, 05 February 2026. The Board considered and approved the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025. The meeting commenced at 3:00 PM IST and concluded at 4:25 PM IST. The Statutory Auditors, MSKA & Associates LLP, have issued a Limited Review Report on these financial results. The detailed financial results, prepared in accordance with Indian Accounting Standards (Ind AS), are available on the company's website and stock exchange websites. The review of the standalone financial results indicated that the company is primarily engaged in diagnostic services. It also noted that the company has assessed the impact of the new Labour Codes, and as of 31 December 2025, the incremental impact is not material. However, the company continues to monitor the finalization of Central/State Rules. A significant point mentioned in the standalone results pertains to a dispute with the Government of Meghalaya concerning a public-private partnership. The recoverability of the company's investments and loans advanced to a step-down subsidiary, aggregating to ₹43.45 lakhs as at 31 December 2025, is under assessment. Based on the information obtained and management's assessment, the company believes the outcome will be in favour of the step-down subsidiary, and therefore, no provision has been considered necessary. The consolidated financial results also noted the company's primary business in diagnostic services. Similar to the standalone results, the impact of the new Labour Codes was assessed as not material for the period ended 31 December 2025. The announcement also listed the subsidiaries included in the consolidated results: Suraksha Specialty LLP, Asian Institute of Immunology & Rheumatology LLP, Suraksha Radiology Private Limited, Suraksha Advanced Radiology Private Limited, Fetomat Wellness Private Limited, and Suraksha Salvia LLP.
